The Jackson Laboratory

Home > JAX^® Mice & Services > News & events > JAX^® NOTES > Issue 512

Newly available JAX^® Mice Strains

JAX^® NOTES Issue 512, Winter 2008

Below is a partial list (11) of newly available JAX^® Mice strains. View our new strains listing for a complete list.

Floxed targeted mutants

B6.129S6(SJL)-Cdh2^tm1Glr/J 007611

This N-cad^flox mutant strain may be used to generate tissue-specific conditional mutants.

B6.Cg-Pdgfra^tm8Sor/EiJ 006492

This strain carries a floxed allele of the platelet derived growth factor receptor alpha (Pdgfra) and may be used with a Cre-expressing strain to produce conditional targeted mutants.

C57BL/6-Gt(ROSA)26Sor^{tm1(HBEGF)Awai}/J 007900

Cre-inducible DTR expression in this floxed iDTR mutant renders cells susceptible to ablation following Diphtheria toxin administration.

STOCK Gt(ROSA)26Sor^{tm1(Notch1)Dam}/J 008159

When used with a Cre-expressing strain, these Rosa^N1-IC- (or Rosa^Notch-) floxed mice may be used to generate conditional mutants for studying the effects of Notch pathway activation.

Targeted mutants

B6.129S4-Ltb4r1^tm1Adl/J 008102

This G protein-coupled receptor BLTR mutant strain may be used to study leukocyte function in inflammation, as well as the role of the LTB4-BLTR pathway linking early immune system activation and multiple classes of acquired immune effector cells.

B6.129-Mgl1^tm1Hed/J 006944

These macrophage galactose N-acetyl-galactosamine specific lectin (MGL1)-deficient mice have slightly higher red blood cell counts, mean corpuscular hemoglobin levels, hematocrit, and mean corpuscular volumes than wild-type controls. Homozygotes have diminished antigen-induced granulation tissue formation. This strain may be useful to study glycosidic molecular interactions and function, antigen-specific and antigen-independent cellular immune response, and hematopoiesis.

B6.129-Tyro3^tm1Grl/J 007937

Homozygotes for this mutation exhibit impaired platelet signaling and secretion and decreased sensitivity to induced pathological thrombosis. They may be used to study thrombosis and platelet aggregation.

B6.129X1-Pomc^tm2Ute/J 008115

Homozygotes for this mutation lack pro-opiomelanocortin-alpha (POMC) and all POMC-derived peptides. They weigh twice as much as wild-type controls and produce no detectable serum adrenocorticotropic hormone (ACTH) or corticosterone. They may be used to study obesity, energy homeostasis, endocrinology, and late-onset tumorigenesis.

Transgenics

B6;C3-Tg(Prnp-MAPT*P301S)PS19Vle/J 008169

This strain expresses the P301S mutant human microtubule-associated protein tau (MAPT) transgene driven by the mouse prion protein (Prnp) promoter. MAPT expression is five-fold higher than that of the endogenous mouse MAPT. This strain may be used to research neurodegenerative tauopathy and Alzheimer's.

B6.Cg-Tg(Thy1-COP4/EYFP)9Gfng/J 007615

This transgenic strain (founder line 9) expresses the light-activated ion channel, Channelrhodopsin-2 (from the green alga Chlamydomonas reinhardtii), and yellow fluorescent protein fusion gene (ChR2-YFP) driven by the mouse thymus cell antigen 1 promoter. ChR2-YFP expression is detected throughout the brain, including in the cortex, hippocampus, thalamus, midbrain, brainstem, cerebellar mossy fibers, and retinal ganglion cells. The strain may be used as an ex vivo or in vivo model to study neural circuitry by light stimulation (e.g., evoked mapping of neural connectivity).

B6.Cg-Tg(CAG-Ub*G76V/GFP)2Dant/J 008112

This ubiquitin/proteasome system (Ub^G76V-GFP/2) reporter strain contains a constitutively active degradation signal (Ub^G76V). It may be used to monitor the role of ubiquitin/proteasome-dependent proteolysis in diverse disorders and to test the efficacy of compounds (including proteasome inhibitors as novel anticancer drugs) on the ubiquitin/proteasome system.